Caprion

Accelerating precision medicine™

Press Release

Wyeth Expands Caprion Biomarker Collaborations to Include Two Clinical Biomarker Programs

Montreal, Canada - June 28, 2005 - Caprion Pharmaceuticals Inc. today announced that Wyeth (NYSE:WYE) has expanded a previously announced collaboration in the discovery and development of protein biomarkers to include two clinical programs currently underway at Wyeth. Wyeth and Caprion had previously and successfully collaborated on preclinical biomarker research in inflammatory disease using CellCarta®, Caprion's proprietary protein expression profiling technology.

The objective of the collaboration is for Caprion to conduct proteomic analyses of human blood plasma samples from patients in two separate phase II clinical trials in the areas of asthma and renal cell carcinoma in order to identify disease state protein biomarkers that may be used in subsequent trials of investigational new drugs.

"This collaboration represents our first example of a pharmaceutical partner expanding its biomarker work with us based on earlier, high-impact studies," noted Lloyd M. Segal, Caprion's President and CEO. "We believe that Wyeth is leading the way in applying the tools of proteomics leaders like us to making better, earlier decisions in the clinical and pre-clinical environment."

###

About Caprion Pharmaceuticals
Caprion is a leading proteomics-based drug discovery company applying CellCarta® to discover and develop innovative products for the diagnosis and treatment of disease. Caprion has established therapeutic antibody discovery partnerships with Abbott Laboratories (NYSE: ABT) in Lung Cancer, and Biogen IDEC (NASDAQ: BIIB) in Colon Cancer, and pharmaco-proteomic discovery collaborations with Wyeth (NYSE: WYE), AstraZeneca (NYSE: AZN), Merck & Co (NYSE: MRK), and Pfizer (NYSE: PFE). Caprion's partners also include IDEXX Laboratories (NASDAQ: IDXX) and Ortho-Clinical Diagnostics (NYSE:JNJ). Caprion's therapeutic antibodies for the prevention of Hemolytic Uremic Syndrome (HUS) resulting from E. coli infection are currently in Phase I clinical trials. For more on Caprion, see www.caprion.com.

FOR MORE INFORMATION CONTACT:

Caprion Pharmaceuticals
Katherine Bonter
(514) 228-3624

Back to news list


Caprion

Accreditations & Certifications

CAP accreditation and CLIA certification

CAP Accredited

Headquarters

+1 514.360.3600
+1 877.776.3443
141 President Kennedy Ave., Suite SB-5658
Montreal, Quebec
CANADA

USA

Primity Bio
48383 Fremont Blvd
Suite 118
Fremont, CA 94538
Tel.: +1 858.229.2529

Serametrix
2235 Farraday Ave,Suite N,
Carlsbad, CA, 92008, USA
Tel: +1 760 652 4060

HistoGeneX
1331 W 75th St #401,
Naperville, IL 60540, USA
Tel: +1 630-473-6655
info@histogenex.com

AUSTRALIA

Serametrix Party Limited
Suite 4/54-60 Briggs Street
Camperdown, NSW, 2050
Australia
+61 2 9168 5908

EUROPE

Caprion Biosciences Inc.
+32 (0) 71 96 23 36
8 rue Adrienne Bolland
6041 Gosselies
BELGIUM

Serametrix
Unit 22, Surrey Technology Centre,
40 Occam Road,
Guildford, Surrey, UK
GU2 7YG
Tel: +44 1483 685599

Antwerp, Belgium
HistoGeneX
Sint-Bavostraat 78
2610 Antwerpen (Wilrijk)
Belgium
Tel: +32 3 50 20 500
Sample Reception: +32 3 50 20 620
Shipments: +32 3 50 20 625

CANADA LAB

201 President Kennedy Ave., Suite PK-3900
Montreal, Quebec
CANADA
+1 514.360.3600
+1 877.776.3443



Follow us

        

Contact

+1 877.776.3443

info@caprion.com